Dipeptidyl peptidase 4 (DPP-4) inhibitors Market Segmental Analysis

The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.5% over the forecast period (2020-2026). The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is sectioned on the basis of drug type. The market is sectioned as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others. Amongst these drug types of the global dipeptidyl peptidase 4 (DPP-4) inhibitors, the Sitagliptin and Saxagliptin are projected to hold the most lucrative share in the market. The key aspects that drive the segmental growth of the dipeptidyl peptidase 4 (DPP-4) inhibitors market include the effectiveness of the drugs. As per the NCBI NLM, the Sitagliptin and Saxagliptin drugs hold the lucrative share in the market owing to their effectiveness on the patients.

Browse the full report description of "Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share & Trends Analysis Report by Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others) Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/dipeptidyl-peptidase-4-inhibitors-market

There has been an upsurge witnessed in the prevalence of diabetes across the globe. As per the WHO, over the last three decades there has been an upsurge in the prevalence of diabetes. As per the IDF, the cases of diabetic were nearly 463 million across the globe in 2019. The cases are projected to increase which is expected to rise to 578 million by 2030 and nearly 700 million by 2045. An increase in the prevalence of diabetes is likely to demand the proper drugs for the treatment. Thus, owing to the market is likely to witness an upsurge over the forecast period.

Market Coverage

• Market number available for – 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Type
• Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
• Competitive Landscape- Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp., and Takeda Pharmaceutical Co. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment/region dominates the market in base year?
• Which segment/region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation

By Type

• Sitagliptin
• Vildagliptin
• Saxagliptin 
• Linagliptin 
• Gemigliptin 
• Anagliptin
• Teneligliptin 
• Others

Global Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation by Region 

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/dipeptidyl-peptidase-4-inhibitors-market